Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Acute maxillary sinusitis

10

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

7

Possibly Marketed Outside US

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial penicillin-binding protein

10

Bile salt export pump

4

Canalicular multispecific organic anion transporter 1

4

Canalicular multispecific organic anion transporter 2

4

Multidrug resistance-associated protein 4

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

10

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1992

4

1997

3

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

10

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Sankyo

4

Fujisawa Pharmaceutical

3

Sjoberg, B.|Undheim, K.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

10

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

10

FDA UNII

10

PUBCHEM

10

EPA CompTox

7

SMS_ID

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER BETA-LACTAM ANTIBACTERIALS

2

BETA-LACTAM ANTIBACTERIALS, PENICILLINS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Third-generation cephalosporins

2

Beta-lactamase sensitive penicillins

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 10 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CEFDINIR

CI0FAO63WC

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1997

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Myeloperoxidase

Conditions:

Acute maxillary sinusitis

Uncomplicated skin and skin-structure infections

Acute exacerbations of chronic bronchitis

Community-acquired pneumonia

Cefdinir is an extended-spectrum, semisynthetic cephalosporin, for oral administration. As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but no...

t all, β-lactamase enzymes. Cefdinir is indicated for the treatment of: Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis, Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections. Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain. Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir.

CEFPODOXIME

7R4F94TVGY

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1992

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bile salt export pump

Multidrug resistance-associated protein 4

Canalicular multispecific organic anion transporter 1

Canalicular multispecific organic anion transporter 2

Bacterial penicillin-binding protein

Conditions:

Acute bacterial exacerbation of chronic bronchitis

Acute, uncomplicated urethral and cervical gonorrhea

Acute maxillary sinusitis

Uncomplicated skin and skin-structure infections

Acute, uncomplicated ano-rectal infections in women

Community-acquired pneumonia

Acute otitis media

Cefpodoxime is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of ...

some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Cefpodoxime is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions: acute otitis media; pharyngitis and/or tonsillitis; community-acquired pneumonia; acute bacterial exacerbation of chronic bronchitis; gonorrhea; uncomplicated skin and skin structure infections; acute maxillary sinusitis and uncomplicated urinary tract infections (cystitis). Common adverse reactions include diarrhea, nausea, vaginal fungal infections, vulvovaginal infections, abdominal pain, headache. Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.

AZIDOCILLIN

R8XDP7L3SL

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Chronic bronchitis

Acute maxillary sinusitis

Azidocillin is a narrow-spectrum, semisynthetic penicillin derivative with antibacterial activity towards Grain-positive and Gram-negative microorganisms, including Haemophilus influenze, against which it is as effective as ampicillin. Azidocillin bi...

nds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis. Azidocillin can be applied in the treatment of inflammation of upper airways, middle ear, sinuses, throat, larynx and palatine tonsils. The substance is excreted with urine in 50-70% in the unchan¬ged form. It binds to the blood plasma proteins in 84%, and its half-life period is 30 min. The side effects are similar as those of benzylpenicillin but occur less frequently.

CEFDINIR, (E)-

61G2M33IGF

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1997

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Myeloperoxidase

Conditions:

Acute maxillary sinusitis

Uncomplicated skin and skin-structure infections

Acute exacerbations of chronic bronchitis

Community-acquired pneumonia

Cefdinir is an extended-spectrum, semisynthetic cephalosporin, for oral administration. As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but no...

t all, β-lactamase enzymes. Cefdinir is indicated for the treatment of: Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis, Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections. Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain. Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir.

CEFDINIR MONOHYDRATE

6E7SN358SE

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1997

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Myeloperoxidase

Conditions:

Acute maxillary sinusitis

Uncomplicated skin and skin-structure infections

Acute exacerbations of chronic bronchitis

Community-acquired pneumonia

Cefdinir is an extended-spectrum, semisynthetic cephalosporin, for oral administration. As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but no...

t all, β-lactamase enzymes. Cefdinir is indicated for the treatment of: Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis, Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections. Side effects include diarrhea, vaginal infections or inflammation, nausea, headache, and abdominal pain. Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox® TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. As with other β-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir.

ANTI-CEFPODOXIME PROXETIL

K9VK627SN2

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1992

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Bile salt export pump

Multidrug resistance-associated protein 4

Canalicular multispecific organic anion transporter 1

Canalicular multispecific organic anion transporter 2

Bacterial penicillin-binding protein

Conditions:

Acute bacterial exacerbation of chronic bronchitis

Acute, uncomplicated urethral and cervical gonorrhea

Acute maxillary sinusitis

Uncomplicated skin and skin-structure infections

Acute, uncomplicated ano-rectal infections in women

Community-acquired pneumonia

Acute otitis media

Cefpodoxime is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of ...

some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Cefpodoxime is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions: acute otitis media; pharyngitis and/or tonsillitis; community-acquired pneumonia; acute bacterial exacerbation of chronic bronchitis; gonorrhea; uncomplicated skin and skin structure infections; acute maxillary sinusitis and uncomplicated urinary tract infections (cystitis). Common adverse reactions include diarrhea, nausea, vaginal fungal infections, vulvovaginal infections, abdominal pain, headache. Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.

CEFPODOXIME SODIUM

3ULP5169B3

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1992

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bile salt export pump

Multidrug resistance-associated protein 4

Canalicular multispecific organic anion transporter 1

Canalicular multispecific organic anion transporter 2

Bacterial penicillin-binding protein

Conditions:

Acute bacterial exacerbation of chronic bronchitis

Acute, uncomplicated urethral and cervical gonorrhea

Acute maxillary sinusitis

Uncomplicated skin and skin-structure infections

Acute, uncomplicated ano-rectal infections in women

Community-acquired pneumonia

Acute otitis media

Cefpodoxime is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of ...

some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Cefpodoxime is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions: acute otitis media; pharyngitis and/or tonsillitis; community-acquired pneumonia; acute bacterial exacerbation of chronic bronchitis; gonorrhea; uncomplicated skin and skin structure infections; acute maxillary sinusitis and uncomplicated urinary tract infections (cystitis). Common adverse reactions include diarrhea, nausea, vaginal fungal infections, vulvovaginal infections, abdominal pain, headache. Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.

CEFPODOXIME PROXETIL

2TB00A1Z7N

Export Data
Search for Structure

Status:

US Approved Rx (2007)

First approved in 1992

Class (Stereo):

CHEMICAL (EPIMERIC)

Targets:

Bile salt export pump

Multidrug resistance-associated protein 4

Canalicular multispecific organic anion transporter 1

Canalicular multispecific organic anion transporter 2

Bacterial penicillin-binding protein

Conditions:

Acute bacterial exacerbation of chronic bronchitis

Acute, uncomplicated urethral and cervical gonorrhea

Acute maxillary sinusitis

Uncomplicated skin and skin-structure infections

Acute, uncomplicated ano-rectal infections in women

Community-acquired pneumonia

Acute otitis media

Cefpodoxime is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of ...

some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Cefpodoxime is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions: acute otitis media; pharyngitis and/or tonsillitis; community-acquired pneumonia; acute bacterial exacerbation of chronic bronchitis; gonorrhea; uncomplicated skin and skin structure infections; acute maxillary sinusitis and uncomplicated urinary tract infections (cystitis). Common adverse reactions include diarrhea, nausea, vaginal fungal infections, vulvovaginal infections, abdominal pain, headache. Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.

AZIDOCILLIN POTASSIUM

7932098147

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Chronic bronchitis

Acute maxillary sinusitis

Azidocillin is a narrow-spectrum, semisynthetic penicillin derivative with antibacterial activity towards Grain-positive and Gram-negative microorganisms, including Haemophilus influenze, against which it is as effective as ampicillin. Azidocillin bi...

nds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis. Azidocillin can be applied in the treatment of inflammation of upper airways, middle ear, sinuses, throat, larynx and palatine tonsils. The substance is excreted with urine in 50-70% in the unchan¬ged form. It binds to the blood plasma proteins in 84%, and its half-life period is 30 min. The side effects are similar as those of benzylpenicillin but occur less frequently.

AZIDOCILLIN SODIUM

0XPT6W6670

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

Conditions:

Chronic bronchitis

Acute maxillary sinusitis

Azidocillin is a narrow-spectrum, semisynthetic penicillin derivative with antibacterial activity towards Grain-positive and Gram-negative microorganisms, including Haemophilus influenze, against which it is as effective as ampicillin. Azidocillin bi...

nds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis. Azidocillin can be applied in the treatment of inflammation of upper airways, middle ear, sinuses, throat, larynx and palatine tonsils. The substance is excreted with urine in 50-70% in the unchan¬ged form. It binds to the blood plasma proteins in 84%, and its half-life period is 30 min. The side effects are similar as those of benzylpenicillin but occur less frequently.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1